China Medical News

According to the 2024 Tariff Adjustment Plan recently published by the Customs Tariff Commission of the State Council, China will waive import tariffs for 62 active pharmaceutical ingredients (API) of anti-cancer drugs and 5 APIs of rare disease drugs, starting from January 1, 2024. The plan covers 1,010 commodities, with interim import tax rates being set lower than most-favored-nation tariffs for the year 2024.

Notably, certain medical products will be exempted from import taxes. Apart from APIs for the anti-cancer and rare disease drugs listed below, medical products such as nirmatrelvir for COVID-19, insulins for diabetes, vaccines, gene therapies, and more will also enjoy interim zero tariffs. (Source: ChemLinked)

For the details, please visit ChemLinked website: https://baipharm.chemlinked.com/news/china-to-waive-import-tariffs-for-active-ingredients-of-anti-cancer-and-rare-disease-drugs-in-2024